BIOMAT Database Logo BIOMAT Database Logo

The CCL20 and CCR6 axis in psoriasis. 2020

Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

Psoriasis is a TNF-α/IL-23/IL-17A-mediated inflammatory skin disease that causes a significant socioeconomic burden in afflicted patients. IL-17A-producing immune cells, including Th17 cells, are crucial effector cells in the development of psoriasis. IL-17A stimulates epidermal keratinocytes to produce CCL20, which eventually recruits CCR6 + Th17 cells into the lesional skin. Thus, the CCL20/CCR6 axis works as a driving force that prepares an IL-17A-rich cutaneous milieu. In this review, we summarize the current research topics on the CCL20/CCR6 axis and the therapeutic intervention of this axis for psoriasis.

UI MeSH Term Description Entries
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D054399 Receptors, CCR6 CCR receptors with specificity for CHEMOKINE CCL20. They are expressed at high levels in T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS. Antigens, CD196,CC Chemokine Receptor 6,CCR6 Receptors,CD196 Antigens,CC Chemokine Receptors 6
D054418 Chemokine CCL20 A CC-type chemokine with specificity for CCR6 RECEPTORS. It has activity towards DENDRITIC CELLS; T-LYMPHOCYTES; and B-LYMPHOCYTES. CCL20 Chemokine,Exodus-1 Chemokine,MIP-3-alpha,Macrophage Inflammatory Protein 3 alpha,SCYA20 Chemokine,Small Inducible Cytokine A20,CCL20, Chemokine,Chemokine, CCL20,Chemokine, Exodus-1,Chemokine, SCYA20,Exodus 1 Chemokine
D058990 Molecular Targeted Therapy Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease. Targeted Molecular Therapy,Molecular Targeted Therapies,Molecular Therapy, Targeted,Targeted Molecular Therapies,Targeted Therapy, Molecular,Therapy, Molecular Targeted,Therapy, Targeted Molecular

Related Publications

Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
The CCL20-CCR6 Axis in Cancer Progression.
July 2020, International journal of molecular sciences,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
Targeting the CCR6-CCL20 axis improves experimental PsA.
August 2021, Nature reviews. Rheumatology,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation.
December 2021, Arthritis & rheumatology (Hoboken, N.J.),
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
The Role of CCL20-CCR6 Axis in Ovarian Cancer Metastasis.
January 2020, OncoTargets and therapy,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology.
May 2019, Immunobiology,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis.
October 2007, Journal of leukocyte biology,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
CCR6/CCL20 chemokine axis in human immunodeficiency virus immunity and pathogenesis.
March 2017, The Journal of general virology,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended?
March 2015, Cytokine,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
The CCR6/CCL20 axis expands RORγt+ Tregs to protect from glomerulonephritis.
July 2023, Kidney international,
Kazuhisa Furue, and Takamichi Ito, and Gaku Tsuji, and Takeshi Nakahara, and Masutaka Furue
CCR6-CCL20 axis as a therapeutic target for autoimmune diseases.
July 2021, Autoimmunity reviews,
Copied contents to your clipboard!